AnaMar
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Medicon Village Scheeletorget 1, Lund, S...Phone Number
+46 462756250Website
www.anamar.comRevenue
$7.9 MillionIndustry
About AnaMar
Is AnaMar your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AnaMar recently announced quarterly report
Check out if AnaMar is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when AnaMar launches new products
AnaMar, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if AnaMar had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if AnaMar has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at AnaMar
Funding: Get notified immidiatlly once AnaMar has new funding data
Recommended Actions
Reach out to Masked Content who joined AnaMar as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
AnaMar is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AnaMar is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AnaMar.
AnaMar Tech Stack
A closer look at the technologies used by AnaMar
AnaMar News & Media
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AnaMar
Anamar is focused on developing a novel medicine aimed at preventing, healing, and slowing organ scarring caused by fibrotic diseases. Their lead product, AM1476, is a highly selective 5HT receptor antagonist that has shown potential in treating both skin and lung manifestations of systemic sclerosis. The company is currently in Phase II of develop... Read More